Tasly Pharmaceutical Group's announcement on the progress of clinical trials and risk warning for T89 to prevent and treat acute plateau reaction adaptation syndrome in the United States FDA.

SZSI · Aug 5

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

天士力关于T89预防及治疗急性高原反应适应症美国FDA临床试验进展暨风险提示公告

Tasly Pharmaceutical Group's announcement on the progress of clinical trials and risk warning for T89 to prevent and treat acute plateau reaction adaptation syndrome in the United States FDA.

Risk Disclaimer

Statement